Medical Issues in Social Security Disability

This book covers shortcomings in submitted medical records, the types of mistakes adjudicators are most likely to make, where generous allowances are provided claimants, ailments and tests frequently overlooked by treating doctors, and more.

Select a format

Revision 21
ISBN: 9781580123525
In Stock
Best value
Revision 21
ISBN: 9781580123525
In Stock
Best value
International Order Inquiry

Product description

View a sample of this title using the ReadNow feature

This 21st revision of Medical Issues in Social Security Disability adds new sections and updates throughout, including updates to various listing discussions that address evaluations in light of SARS-CoV-2 (COVID-19) infection. New and updated sections include:

New and Updated

  • Chapter 1, §1.01.1.a, updated fibromyalgia information regarding cause.
  • Chapter 1, § 1.01.1.a, pelvic fractures and mortality.
  • Chapter 4, §4.02.1.a, diastolic heart failure.
  • Chapter 4, §4.09.1.b, heart transplants, especially the presence of cardiac allograft
  • Chapter 4, §4.12.2, residual functional capacity; peripheral arterial disease.
  • Chapter 4, §4.05.2, hypertrophic cardiomyopathy (HCM)
  • Chapter 4, §4.02.3, hypertrophic cardiomyopathy and exertional limitations
  • Chapter 4, §4.05.2, obesity cardiomyopathy.
  • Chapter 4, §4.02.3, exertional limitations in diastolic heart failure.
  • Chapter 4, §4.04.1.a, Covid-19 inflammation of coronary arteries and the risk of a heart attack
    and persistence of the virus in coronary lesions; presence of the virus in coronary lesions.
  • Chapter 7, §7.08.1.a, hemophilia and gene therapy for factor VIII deficiency.
  • Chapter 7, §7.05.1.a, new gene therapies cleared for treatment of sickle cell disease.
  • Chapter 11, §11.04.02, exertional limitations for those with internal carotid artery stenosis.
  • Chapter 12, §12.02.1.a, SARS-CoV-2 persistence in the gut and decreased serotonin and
    depression; Long Covid mental symptoms.
  • Chapter 13, §13.06.1.a, survival predictability for AML after start of treatment and after bone
    marrow transplant.
  • Chapter 13, §13.02.3, the cause of “Chemobrain.”
  • Chapter 14, 14.01.b, the danger of monkeypox (Mpox) in HIV infections.
  • Chapter 14, §14.06.a, updated information on the VEXAS syndrome.


eBooks, CDs, downloadable content, and software purchases are noncancelable, nonrefundable and nonreturnable. Click here for more information about LexisNexis eBooks. The eBook versions of this title may feature links to Lexis+® for further legal research options. A valid subscription to Lexis+® is required to access this content.